TY - JOUR
T1 - Impact of diabetes mellitus on the prognosis of patients with oral squamous cell carcinoma
T2 - A retrospective cohort study
AU - Wu, Cheng Hsien
AU - Wu, Tzu Ying
AU - Li, Chia Chen
AU - Lui, Man Tin
AU - Chang, Kuo Wei
AU - Kao, Shou Yen
N1 - Funding Information:
ACKNOWLEDGMENT We thank Dr. Harn-Shen Chen from Department of Endocrinology & Metabolism, Taipei Veterans General Hospital for his critical comment in diabetes stratification in the present study. This work was supported by grant V98A-031 and V98A-035 of the Taipei Veterans General Hospital, by grant NSC96-2314-B-075-063-MY3 of the National Science Council, Executive Yuan, Taiwan (ROC). The authors declare no conflicts of interest.
PY - 2010/8
Y1 - 2010/8
N2 - Background: Diabetes mellitus (DM) is a prevalent chronic metabolic disease reported to affect the treatment outcomes of malignancies. This study explores the impact of diabetes on the prognosis of oral squamous cell carcinoma (OSCC). Materials and Methods: Clinicopathological characteristics and survival in terms of overall survival (OS), recurrence-free survival (RFS), and cancer-specific survival (CSS) of patients with OSCC who underwent surgical intervention at the Taipei Veterans General Hospital between 2002 and 2005 were stratified by diabetic status and compared. Results: Patients with DM tend to have a lower OS, RFS, and CSS compared with nondiabetics (adjusted hazard ratio [HR] = 2.22, 2.42, and 2.16, respectively) even in less aggressive tumor stages (stage I and II). In advanced tumors, diabetic patients who were not prescribed adjuvant therapy had a significantly higher recurrence rate than nondiabetic patients (HR = 2.66). However, there was no significant difference in treatment outcome in patients with locally advanced tumors amenable to receive adjuvant therapy, even with the delayed initiation of adjuvant therapy in the DM group (49.1 ± 22.3 days vs. 40.0 ± 16.6 days, P =.04). DM was also associated with a higher frequency of perineural invasion (adjusted odds ratio [OR] = 2.53). Conclusion: DM status could be a prognostic factor for OSCC, particularly for its effect in the survival and perineural invasion. Although diabetes-associated comorbidities may impair decision making toward less aggressive therapeutic modality, adjuvant treatment may be essential for DM patients to improve their survival.
AB - Background: Diabetes mellitus (DM) is a prevalent chronic metabolic disease reported to affect the treatment outcomes of malignancies. This study explores the impact of diabetes on the prognosis of oral squamous cell carcinoma (OSCC). Materials and Methods: Clinicopathological characteristics and survival in terms of overall survival (OS), recurrence-free survival (RFS), and cancer-specific survival (CSS) of patients with OSCC who underwent surgical intervention at the Taipei Veterans General Hospital between 2002 and 2005 were stratified by diabetic status and compared. Results: Patients with DM tend to have a lower OS, RFS, and CSS compared with nondiabetics (adjusted hazard ratio [HR] = 2.22, 2.42, and 2.16, respectively) even in less aggressive tumor stages (stage I and II). In advanced tumors, diabetic patients who were not prescribed adjuvant therapy had a significantly higher recurrence rate than nondiabetic patients (HR = 2.66). However, there was no significant difference in treatment outcome in patients with locally advanced tumors amenable to receive adjuvant therapy, even with the delayed initiation of adjuvant therapy in the DM group (49.1 ± 22.3 days vs. 40.0 ± 16.6 days, P =.04). DM was also associated with a higher frequency of perineural invasion (adjusted odds ratio [OR] = 2.53). Conclusion: DM status could be a prognostic factor for OSCC, particularly for its effect in the survival and perineural invasion. Although diabetes-associated comorbidities may impair decision making toward less aggressive therapeutic modality, adjuvant treatment may be essential for DM patients to improve their survival.
UR - http://www.scopus.com/inward/record.url?scp=77954952886&partnerID=8YFLogxK
U2 - 10.1245/s10434-010-0996-1
DO - 10.1245/s10434-010-0996-1
M3 - Article
C2 - 20224856
AN - SCOPUS:77954952886
SN - 1068-9265
VL - 17
SP - 2175
EP - 2183
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 8
ER -